Table of Contents Table of Contents
Previous Page  154 / 398 Next Page
Information
Show Menu
Previous Page 154 / 398 Next Page
Page Background

149

in all cases of osteonecrosis of the jaw, provided that the systemic

condition of the patient permits the surgical approach.

http://dx.doi.org/10.1016/j.ijom.2017.02.513

Palatal hyperpigmentation associated with imatinib mesylate

therapy: a report of 2 rare cases

A. Shi

∗

, Q.Q. Lee, J.B. Lai, C. Sim

Department of Oral and Maxillofacial Surgery, National Dental

Centre Singapore, Singapore

Background:

Imatinib mesylate (Glivec

®

, Gleevec

®

, STI-571) is

a tyrosine kinase inhibitor currently used as the first-line medi-

cation for a number of malignant and haematological conditions.

One major indication of its use is for chronic myeloid leukaemia to

increase survival rates of these patients

. 1 A

number of minor side

effects are commonly reported including dermatological hypopig-

mentation. Comparatively, reports of mucosal hyperpigmentation

are rare

. 2

Case report:

We report two rare cases of hyperpigmentation of

the palatal mucosa associated with imatinib mesylate therapy to

treat chronic myeloid leukaemia. A diffuse, bluish-grey lesion

located at the hard palate was observed in both patients. Inci-

sional biopsies were performed and histological features of benign

hyperpigmentation were described.

Discussion:

c-Kit signalling may have a role to play in hyper-

pigmentation of the oral mucosa. It is important for clinicians

to recognise hyperpigmentation of the palatal mucosa associated

with imatinib mesylate therapy and distinct them frommelanoma.

They need to consider it in their differential diagnoses of oral

melanosis.

Conclusion:

Clinicians should be cognisant that hyperpigmenta-

tion of the palatal mucosa is a rare side effect of imatinib mesylate

therapy.

Reference

Gambacorti-Passerini, C., Antolini, L., Mahon, F. X., Guilhot, F., Deininger,

M., Fava, C., et al. (2011). Multicenter independent assessment of out-

comes in chronic myeloid leukemia patients treated with imatinib.

J Natl

Cancer Inst

,

103

, 553–561.

McPherson, T., Sherman, V., & Turner, R. (2009). Imatinib-associated

hyperpigmentation, a side effect that should be recognized.

J Eur Acad

Dermatol Venereol

,

23

, 82–83.

http://dx.doi.org/10.1016/j.ijom.2017.02.514

Adolescence noma with facial defect and trismus (case

report)

M. Sylvyana

∗

, S. Adiantoro, A. Arumsari

Department of Oral and Maxillofacial Surgery, RSUP Dr. Hasan

Sadikin, Bandung, Indonesia

Noma is described as gangrenous infection of the oral and max-

illofacial region. Patients with noma are mostly children with

malnutrition and immunocompromised. Since the development on

health care in Indonesia and the availability of antibiotics, noma

cases become very rare.

This paper report 2 cases of adolescence noma with orofacial

defect and trismus.

Case 1: A 30-year-old male was referred to the oral and max-

illofacial surgery clinic at Dr. Hasan Sadikin Hospital from ETT

Department. The chief complaint was large defect of right lip with

restricted mouth opening. The examination revealed tuberculosis

(TB) infection with pseudomembrane at larynx. A further check

on human immunodeficiency virus (HIV) infection correlatedwith

clinical symptoms.

Case 2: A 38-year-old female presented to the oncology depart-

ment with orofacial defect and trismus. Patient showed features of

malnutrition. The oncology department has had the diagnosis of

inflammatory pseudotumour upon the biopsy. Dental examination

showed the impacted teeth of 38 and massive periodontal infection

from 33 to 38.

Treatment to both cases proceeded with regional flap for defect

closure, muscular release for contracture area. The surgical treat-

ment followed with nutritional care and physiotherapy. The patient

with TB and suspected HIV, was referred to the internal medicine

department.

http://dx.doi.org/10.1016/j.ijom.2017.02.515

Aetiology of oral health problems in Crohn’s disease

C.X.W. Tan

∗

, H.S. Brand, S. Iqbal, T. Forouzanfar

VU Medical Centre, Amsterdam, The Netherlands

Background:

Inflammatory bowel disease (IBD) not only affects

the intestinal tract but may also have oral manifestations. The

aetiology of these oral manifestations is not exactly known.

Objectives:

To investigate whether inflammation of the intestine

is an aetiological factor of the oral manifestations or that there is

another aetiological factor that causes both the intestinal and oral

manifestations.

Methods:

To exclude the inflamed intestine as an aetiological

factor, this study was conducted in association with the Stoma

Association Netherlands. A validated oral health questionnaire

was distributed by email to the members of this association. The

self-reported oral health from patients with a stoma due to IBD

was compared with age-and gender-matched patients with a stoma

due to colon cancer.

Findings:

The questionnaire was completed by 773 patients. 12%

had a stoma as a result of Crohn’s disease, 18% due to ulcerative

colitis and 43% due to colon cancer. Patients with Crohn’s disease

reported significantly more oral health problems than patients with

a stoma due to colon cancer or ulcerative colitis. Crohn patients

with a stoma especially suffered more frequently from aphthae

and discolorations of the oral mucosa. The increased incidence of

oral problems in Crohn’s patients was not related to differences in

tooth brushing frequency or interdental space cleaning.

Conclusion:

Patients with Crohn’s disease have an increased

risk for oral health problems, which remains after removal of

the affected part of the intestine, suggesting a general increased

susceptibility of Crohn’s disease patients for oral health problems.

http://dx.doi.org/10.1016/j.ijom.2017.02.516